Medicine and Dentistry
Neoplasm
100%
Adenocarcinoma
65%
Colorectal Carcinoma
35%
Rectum Cancer
35%
Hereditary Nonpolyposis Colorectal Cancer
34%
Diseases
31%
Adenoma
29%
Cytoreductive Surgery
28%
Magnetic Resonance Imaging
27%
Overall Survival
24%
Diagnosis
23%
Surgery
22%
Recurrent Disease
20%
Hyperthermic Intraperitoneal Chemotherapy
19%
Hazard Ratio
18%
Polyp
18%
Pelvis
17%
Appendix Tumor
17%
Neuroendocrine Tumor
15%
Chemoradiotherapy
15%
Malignant Neoplasm
15%
Retroperitoneal Lymph Node Dissection
14%
Carcinogenesis
14%
Cancer Staging
14%
Lymph Node
13%
Computer Assisted Tomography
13%
Familial Adenomatous Polyposis
13%
Polyposis
13%
Metastatic Carcinoma
12%
Peritoneum Metastasis
12%
Mucosa
12%
Rectum Carcinoma
11%
Neoadjuvant Therapy
11%
Immunity
11%
Pathologist
10%
Mucin
10%
Recurrence Free Survival
10%
DNA Mismatch Repair
10%
Colon Carcinoma
9%
Precancerous Condition
9%
Tumor Marker
9%
Adenomatous Polyposis Coli
8%
Genetic Disorder
8%
Carcinoma
8%
Tubular Adenoma
8%
Patient Care
8%
Carcinoid
7%
Immunohistochemistry
7%
Cancer
7%
Patient Selection
7%
Keyphrases
Colorectal Cancer
47%
Appendiceal Adenocarcinoma
46%
Lynch Syndrome
31%
Tumor
25%
Adenoma
20%
Microsatellite Instability-high (MSI-H)
16%
Chemotherapy
15%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
12%
Familial Adenomatous Polyposis
12%
Overall Survival
11%
Peritoneal Metastasis
11%
Computed Tomography
11%
Rectal Adenocarcinoma
11%
Resection
11%
Neoadjuvant Chemoradiotherapy (nCRT)
10%
Cytoreductive Surgery
10%
Pancreas
9%
Pathological Response
9%
Genomic Landscape
9%
Lateral Lymph Node Dissection
9%
Poor Differentiation
9%
Hazard Ratio
9%
Confidence Interval
9%
Magnetic Resonance Imaging
9%
Surgical Resection
8%
Premalignant Lesions
8%
Appendiceal Neoplasms
8%
Neoantigen
7%
Anatomic
7%
Epithelial Neoplasm
7%
Cancer Staging
7%
Neoplasms
7%
Mismatch Repair
7%
Appendiceal
7%
Recurrence-free Survival
7%
Tumor Deposits
6%
Liver
6%
Patient-derived Xenograft
6%
Consensus Molecular Subtypes
6%
Histological Grade
6%
Secondary Cytoreductive Surgery
5%
Neoadjuvant Therapy
5%
Localized Disease
5%
Bevacizumab
5%
Colectomy
5%
MSH2
5%
Patient Selection
5%
Colorectal Adenoma
5%
Total Neoadjuvant Therapy
5%
In Silico
5%